Evidence map›Paper›PMID 19299018›Full record

ArticleEnvironment international2010

Triclosan is a potent inhibitor of estradiol and estrone sulfonation in sheep placenta.

Margaret O James, Wenjun Li, David P Summerlot, Laura Rowland-Faux, Charles E Wood

Open access · greenAbstract read
In one paragraph

Article in Environment international, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 4 pooled it
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 4 syntheses or guidelines pooled it, 134 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Current approaches and advances in placental toxicology.Trends in endocrinology and metabolism: TEM · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Inhibition of Estrogen Sulfotransferase (Journal of the American Society of Nephrology : JASN · 2020
    Article
  17. Occurrence of selected endocrine disrupting compounds in the eastern cape province of South Africa.Environmental science and pollution research international · 2020
    Article
  18. Review
  19. Article
  20. Triclosan: An Update on Biochemical and Molecular Mechanisms.Oxidative medicine and cellular longevity · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Margaret O JamesDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32610-0485, USA. mojames@ufl.edu
Wenjun Li
David P Summerlot
Laura Rowland-Faux
Charles E Wood
University of Florida · US

Funding

Renal Transporters and Fetal NeuroendocrinologyR01HD057561 · NICHD · UNIVERSITY OF FLORIDA · PI WOOD, CHARLES E · 2009 to 2013
$1.4M
NICHD NIH HHS R01 HD057561
6 · The paper itself

Abstract

The personal care product Triclosan, 5-chloro-2(2,4-dichlorophenoxy)-phenol, is widely used in consumer products as an antibacterial agent and is increasingly found in the environment as a contaminant of sewage sludge and wastewater. This compound has been identified in plasma and urine of people in the United States, Sweden and Australia. Triclosan is known to inhibit sulfonation of phenolic xenobiotics and is structurally related to inhibitors of estrogen sulfotransferase, such as polychlorobiphenylols. In pregnancy, the placenta is an important source of estrogen, which is needed for normal fetal development and successful parturition, and estrogen sulfotransferase is thought to play an important role in regulation of estrogen availability. In this study, we examined the effect of Triclosan on sheep placental cytosolic sulfotransferase activity with 17-beta-estradiol and estrone as substrates. For comparison, we studied the effects of 4-hydroxy-3,3',4',5-tetrachlorobiphenyl and 2'-hydroxytriclocarban on estradiol sulfonation. The apparent K(m) for placental cytosolic sulfotransferase activity with estradiol as substrate was 0.27 ± 0.06 nM (mean ± S.D., n = 3 individuals) and with estrone as substrate was 1.86 ± 0.22 nM. Partial substrate inhibition was observed with estradiol at concentrations higher than 10-20 nM, as is typical of estrogen sulfotransferases (SULT1E1) in other species. Studies of the effect of Triclosan on estrogen sulfotransferase activity were conducted with several concentrations (0.1-6 nM) of estradiol and with 2 nM estrone. Triclosan was a very potent inhibitor of both estradiol and estrone sulfonation. For estradiol the inhibition was shown to be mixed competitive/uncompetitive, with K(ic) of 0.09 ± 0.01 nM and K(iu) of 5.2 ± 2.9 nM. The IC(50) for inhibition of estrone sulfonation was 0.60 ± 0.06 nM. At an environmentally relevant concentration of 1 µM, Triclosan was not a substrate for glucuronidation in sheep placental microsomes. Triclosan could be sulfonated in placental cytosol with K(m) 1.14 ± 0.18 µM and V(max) 160 ± 26 pmol/min/mg protein, however the calculated rates of Triclosan sulfonation were negligible at the low nM concentrations that potently inhibit estrogen sulfonation. The high potency of Triclosan as an inhibitor of estrogen sulfotransferase activity raises concern about its possible effects on the ability of the placenta to supply estrogen to the fetus, and in turn on fetal growth and development.

Indexed as

AnimalsEnvironmental PollutantsEnzyme InhibitorsEstradiolEstroneFemaleInhibitory Concentration 50KineticsMicrosomesPlacentaPregnancySheepSulfonic AcidsSulfotransferasesTriclosanEnvironmental PollutantsEnzyme InhibitorsEstradiolEstroneestrone sulfotransferaseSulfonic AcidsSulfotransferasesTriclosan

Identifiers

PMID19299018
PMCPMC4789100
OpenAlexW1980292711

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.